CD274 and neoplasm: Biomarkers of response to ICB described for other cancers include programmed death ligand 1 (PD-L1) positivity on tumor and immune cells, expression of an IFN-γ gene signature, the status of the tumor immune microenvironment, T cell infiltration, microsatellite instability, high tumor mutational burden (TMB), and DNA mismatch repair (dMMR) defects, among others (35–37).